November 02, 2025

Get In Touch

Ipca Labs incorporates new wholly owned arm in Federal Republic of Germany

Mumbai: Ipca Labs has announced thatthe Company has incorporated a wholly owned subsidiary named 'Ipca Pharmaceuticals GmbH' in the Federal Republic of Germany. The newly formed subsidiary has an initial paid-up capital of €25,000. The primary objective of Ipca Pharmaceuticals GmbH is to hold product registrations, participate in institutional and other business activities, and undertake the distribution of generic formulations across the country. Read also:Ipca Labs appoints Dr Nagaji Ambabhai Vekariya as President - CRD Established in 1949, lpca is a pharmaceutical company. lpca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients. For more than 70 years, lpca has been a crucial healthcare partner in over 120 countries across the globe. lpca markets its branded formulations in India and rest of the world markets and generic formulations in United States, Europe, United Kingdom, Canada, Australia & New Zealand. APls manufactured by lpca are marketed across the globe.

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!